Genetic Associations With White Matter Hyperintensities Confer Risk of Lacunar Stroke
- Other version(s) of this article
You are viewing the most recent version of this article. Previous versions:
Abstract
Background and Purpose—
White matter hyperintensities (WMH) are increased in patients with lacunar stroke. Whether this is because of shared pathogenesis remains unknown. Using genetic data, we evaluated whether WMH-associated genetic susceptibility factors confer risk of lacunar stroke, and therefore whether they share pathogenesis.
Methods—
We used a genetic risk score approach to test whether single nucleotide polymorphisms associated with WMH in community populations were associated with magnetic resonance imaging–confirmed lacunar stroke (n=1,373), as well as cardioembolic (n=1,331) and large vessel (n=1,472) Trial of Org 10172 in Acute Stroke Treatment subtypes, against 9,053 controls. Second, we separated lacunar strokes into those with WMH (n=568) and those without (n=787) and tested for association with the risk score in these 2 groups. In addition, we evaluated whether WMH-associated single nucleotide polymorphisms are associated with lacunar stroke, or in the 2 groups.
Results—
The WMH genetic risk score was associated with lacunar stroke (odds ratio [OR; 95% confidence interval [CI]]=1.14 [1.06–1.22]; P=0.0003), in patients both with and without WMH (WMH: OR [95% CI]=1.15 [1.05–1.26]; P=0.003 and no WMH: OR [95% CI]=1.11 [1.02–1.21]; P=0.019). Conversely, the risk score was not associated with cardioembolic stroke (OR [95% CI]=1.03 [0.97–1.09]; P=0.63) or large vessel stroke (OR [95% CI]=0.99 [0.93,1.04]; P=0.39). However, none of the WMH-associated single nucleotide polymorphisms passed Bonferroni-corrected significance for association with lacunar stroke.
Conclusions—
Genetic variants that influence WMH are associated with an increased risk of lacunar stroke but not cardioembolic or large vessel stroke. Some genetic susceptibility factors seem to be shared across different radiological manifestations of small vessel disease.
Introduction
Cerebral small vessel disease (SVD) affects the small perforating arteries of the brain and is characterized radiologically by several features, including white matter hyperintensities (WMH), subcortical lacunar infarcts, intracerebral hemorrhages, and cerebral microbleeds.1 Despite the considerable impact of SVD on health through increased risk of stroke and vascular dementia, the pathophysiological mechanisms underlying SVD remain largely unknown. Pathological findings in diseased vessels include lipohyalinosis and microatheroma,2,3 whereas in the parenchyma findings include myelin pallor, enlargement of perivascular spaces, and gliosis.4 Many of these findings are common to both WMH and lacunar stroke.5 However, pathological studies have been hampered by methodological and phenotypic inconsistencies.5 In addition, little is known about the extent to which underlying pathogenesis is shared across the radiological manifestations. WMH are increased in lacunar stroke6,7; more so than in other pathological subtypes of stroke, which may indicate that shared pathological processes underlie the 2. In addition, both confluent WMH and lacunar infarcts are a common finding in Mendelian forms of SVD such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,8 although the underlying arterial pathology is considerably different to that of sporadic SVD. However, aside from these exceptions and shared cardiovascular risk factors such as hypertension, few molecular processes have been robustly shown to impact on both lacunar stroke and WMH.
Genetic studies can provide novel insights into SVD and the nature of the relationship between its manifestations. In particular, genome-wide association studies have recently identified multiple genetic variants associated with WMH in community-dwelling individuals9 and have been used to show that common variants in COL4A2, a gene associated with monogenic SVD, influence sporadic SVD.10 In addition, genome-wide association studies provide a means of interrogating the relationship between complex traits and assessing whether such traits share pathogenesis. Polygenic risk score approaches can be used to investigate whether 2 conditions are genetically related by testing whether the cumulative effect of trait-associated single nucleotide polymorphisms (SNPs) associated with the first trait influence a second trait. Such approaches have previously been used to assess the influence of risk factors on stroke11,12 and to assess the shared susceptibility between stroke and migraine.13
In this analysis, we evaluated the impact of common genetic variants associated with WMH from community populations on the risk of lacunar stroke in a well-characterized population of magnetic resonance imaging (MRI)–confirmed lacunar stroke cases and controls. As heterogeneity in the pathology underlying lacunar stroke has been hypothesized,14 and to test whether an association with lacunar stroke was present in individuals without substantial WMH, we separated our lacunar stroke cases into those with substantial WMH and those with no or mild WMH, testing the influence of WMH-associated variants on these subgroups, as well as on cardioembolic and large vessel strokes. We first used a genetic risk score approach to evaluate the overall evidence that WMH-associated variants affect stroke phenotypes, and then second evaluated whether each of the specific genetic variants is associated with lacunar stroke in both the groups with and without WMH.
Materials and Methods
Study Participants
The study data set consisted of stroke cases obtained from hospital admissions in the UK and Germany (DNA-lacunar, Genes and Ischaemic Stroke [GENESIS] and Wellcome Trust Case Control Consortium 2 [WTCCC2] study), Australia (Australian Stroke Genetics Collaborative [ASGC]), Italy (Milano—Besta Stroke Register [BSR]), and Belgium (Leuven Stroke Study [LSS]), as well as 9053 controls consisting of ancestry-matched individuals from each of the respective case populations (Table). These data sets have been described in detail in previous publications.15–18 Genotyping and imputation of the individuals are described in the online-only Data Supplement. Briefly, all data sets were genotyped on commercially available Illumina arrays and imputed to 1000 Genomes phase 3 using SHAPEIT v2 (for phasing) and IMPUTE v2.2.2 (for imputation).
SNP | Gene Region | CHR | BP (hg19) | RA | OR (95% CI); P Value | ||
---|---|---|---|---|---|---|---|
Lacunar Stroke | Lacunar Stroke w/WMH | Lacunar Stroke w/out WMH | |||||
rs7214628 | TRIM65 | 17 | 73882148 | G | 1.02 (0.90–1.15); 0.78 | 1.08 (0.92–1.28); 0.33 | 0.94 (0.80–1.11); 0.47 |
rs72848980 | NEURL | 10 | 105319409 | G | 1.13 (0.99–1.29); 0.08 | 1.15 (0.97–1.38); 0.12 | 1.10 (0.92–1.30); 0.30 |
rs7894407 | PDCD11 | 10 | 105176179 | T | 1.04 (0.94–1.15); 0.49 | 1.03 (0.90–1.18); 0.65 | 1.01 (0.88–1.15); 0.89 |
rs12357919 | SH3PXD2A | 10 | 105438112 | T | 1.13 (0.99–1.29); 0.07 | 1.13 (0.95–1.35); 0.15 | 1.12 (0.94–1.33); 0.19 |
rs7909791 | SH3PXD2A | 10 | 105613178 | A | 1.14 (1.03–1.27); 0.01* | 1.15 (1.01–1.32); 0.04* | 1.19 (1.04–1.36); 0.01* |
rs78857879 | EFEMP1 | 2 | 56135099 | A | 0.98 (0.82–1.15); 0.77 | 1.03 (0.83–1.28); 0.77 | 0.90 (0.72–1.13); 0.37 |
rs2984613 | PMF1-BGLAP | 1 | 156197380 | C | 1.10 (0.99–1.22); 0.07 | 1.13 (0.99–1.30); 0.07 | 1.06 (0.93–1.20); 0.41 |
rs11679640 | HAAO | 2 | 43141485 | C | 0.91 (0.81–1.03); 0.15 | 0.89 (0.76–1.04); 0.13 | 0.95 (0.81–1.12); 0.55 |
rs72934505 | NBEAL1 | 2 | 203916487 | T | 1.24 (1.07–1.45); 0.004* | 1.29 (1.05–1.59); 0.01* | 1.19 (0.98–1.45); 0.08 |
rs17148926 | LOC10050584 | 5 | 121510586 | C | 0.87 (0.76–1.00); 0.05 | 0.87 (0.73–1.04); 0.14 | 0.88 (0.74–1.05); 0.17 |
rs941898 | EVL | 14 | 100599437 | G | 1.12 (1.01–1.25); 0.04* | 1.09 (0.95–1.26); 0.22 | 1.14 (0.99–1.30); 0.07 |
rs6942756 | AHCYL2 | 7 | 128886821 | G | 1.07 (0.96–1.20); 0.22 | 1.05 (0.91–1.22); 0.50 | 1.11 (0.96–1.28); 0.15 |
rs2883428 | XM_0039600 | 1 | 239571364 | G | 1.00 (0.89–1.11); 0.96 | 1.04 (0.90–1.20); 0.62 | 0.98 (0.85–1.14); 0.83 |
rs962888 | C1QL1 | 17 | 43059071 | G | 1.04 (0.94–1.17); 0.44 | 1.09 (0.94–1.26); 0.24 | 1.00 (0.87–1.15); 0.99 |
rs9515201 | COL4A2 | 13 | 111040798 | A | 1.15 (1.03–1.27); 0.01* | 1.13 (0.99–1.30); 0.07 | 1.14 (1.00–1.31); 0.06 |
Phenotype Classification
Subtyping of the ASGC, WTCCC2, GENESIS, BSR, and LSS groups was initially performed using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification,19 using clinical assessment as well as brain and vascular imaging where available. For this analysis, we considered only cardioembolic, large vessel, and small vessel subtypes. For the cases that were classified as small vessel stroke under TOAST and had accompanying MRI, as well as all cases from UK Young Lacunar Stroke Study (DNA-lacunar) which included only cases with the TOAST SVD subtype, we performed further characterization, as follows. All MRI scans were centrally reviewed by 1 physician (H.S.M.). The diagnosis of lacunar stroke was confirmed using the following criteria. Lacunar stroke was defined as a clinical lacunar syndrome,20 with an anatomically compatible lesion on MRI (subcortical infarct ≤15 mm in diameter). For MRIs performed in the acute phase, the diagnosis was made by an acute lacunar infarct on DWI. For scans not performed in the acute phase, the diagnosis was made by a lacunar syndrome in combination with a lacunar infarct visualized on T1 and fluid-attenuated inversion recovery as a cavitated lesion in an anatomically appropriate location. Exclusion criteria were as follows: stenosis >50% in the extra- or intracranial cerebral vessels; cardioembolic source of stroke, defined according to the TOAST criteria as high or moderate probability; subcortical infarct >15 mm in diameter, as these can be caused by embolic mechanisms (striatocapsular infarcts); any other specific cause of stroke (eg, lupus anticoagulant, cerebral vasculitis, dissection, monogenic forms of stroke, such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). For each individual with a lacunar stroke, we characterized the degree of WMH using the semiquantitative Fazekas scale,21 which classifies individuals into 4 groups ranging from none (0) to severe (3). Based on this grading, we then divided the lacunar stroke cases into those with and without WMH: (1) no WMH—patients with only mild or absent leukoaraiosis (Fazekas grade 0 or 1) and (2) WMH—patients with moderate or severe leukoaraiosis (Fazekas grade ≥2).
Genetic Risk Score Analyses
For each of the 18 SNPs associated with WMH in community populations in a recent study (8 genome-wide and 10 with P<1×10−5 in Europeans or overall),9 we generated an unweighted risk score for each individual in our data set by counting the number of risk alleles and summing across all SNPs. We used an unweighted approach, rather than an approach weighted on the log of the odds ratio (OR), as effect sizes were not reported for the published associations with WMH.9 Three of the SNPs (rs186314186, rs150695384, and rs117126031) were rare and not well imputed in our data set so were not included. Within each data set, we then converted each individual’s risk score to a Z-score using the standard transformation. We then used logistic regression to estimate the influence of the risk score on each stroke outcome, including ancestry-informative principal components to control for population stratification and meta-analyzing the results using a fixed-effects inverse variance weighted approach. We tested for association of the genetic risk score with lacunar, cardioembolic, and large vessel stroke.
To investigate whether an association with lacunar stroke was independent of WMH, we performed the same analysis on 2 subgroups of lacunar stroke stratified on the presence of substantial WMH (Fazekas ≥2). As the purpose of this analysis was to identify whether the observed association with lacunar stroke was independent of WMH, we did not perform the same analyses in the other subtypes. All ORs reported are per 1 SD change in the normally distributed risk score. We set the criteria for statistical significance at P<0.01, Bonferroni-correcting for the 5 tests.
Single SNP Analyses
In addition, we tested the association of each of the 15 available SNPs with lacunar stroke and the 2 subgroups based on the presence or absence of WMH. For each SNP we performed analyses separately in the 3 batches, including the first 10 ancestry-informative principal components in each analysis. We meta-analyzed the results using a fixed-effects inverse-variance weighted approach. We set the significance threshold at P<0.0011, correcting for the 15 SNPs in each of the 3 phenotypes (45 tests in total). All analyses were performed using the R statistical software.
Results
Cohort Characteristics
The final cohort consisted of 4176 stroke cases, including 1,373 lacunar stroke cases (mean age [SD]=60.0 [11.3] years; 68.0% men), subtyped into 568 with WMH (mean age [SD]=65.1 [10.9] years; 65.0% men) and 787 without WMH (mean age [SD]=56.0 [9.9] years; 70.2% men), 1,331 cardioembolic strokes (mean age [SD]=72.8 [10.6] years; 52.7% men), and 1,472 large vessel strokes (mean age [SD]=66.9 [11.1] years; 67.3% men) and 9,053 controls (mean age [SD]=58.4 [10.7] years [age not available in 2437 of WTCCC2-UK controls]; 52.2% men). Information on WMH volumes was not available in controls. As inclusion in the MRI-informed lacunar stroke analysis depended on the availability of an MRI and confirmation of a lacunar infarct, proportions of lacunar stroke cases varied greatly between studies (Figure 1).

Figure 1. Cohort characteristics. ASGC indicates Australian Stroke Genetics Collaborative; CE, cardioembolic stroke; GENESIS, Genes and Ischaemic Stroke; LSS, Leuven Stroke Study; LVD, large vessel disease; MRI, magnetic resonance imaging; SVD, small vessel disease; WMH, white matter hyperintensities; and WTCCC2, Wellcome Trust Case Control Consortium 2.
Genetic Risk Score Analyses
A genetic risk score comprises 15 SNPs associated with WMH in community populations was significantly associated with lacunar stroke (OR [95% confidence interval [CI]=1.14 [1.06–1.22]; P=0.0003; Figure 2). The association was slightly stronger, although not significantly so, in the group with WMH (OR [95% CI]=1.15 [1.05–1.26]; P=0.003) and slightly weaker and not reaching Bonferroni-corrected significance in the group without substantial WMH (OR [95% CI]=1.11 [1.02–1.21]; P=0.019). Conversely, the risk score was not associated with cardioembolic (OR [95% CI]=1.03 [0.97–1.09]; P=0.39) or large vessel stroke (OR [95% CI]=0.99 [0.93–1.04]; P=0.63).

Figure 2. Association of white matter hyperintensities (WMH) Genetic Risk Score with ischemic stroke subtypes. GENESIS indicates Genes and Ischaemic Stroke; LSS, Leuven Stroke Study; and MCLSC, magnetic resonance imaging-confirmed lacunar stroke collaboration (Australian Stroke Genetics Collaborative [ASGC], Wellcome Trust Case Control Consortium 2 [WTCCC2-UK], Wellcome Trust Case Control Consortium 2 [WTCCC2]-Germany and Milano studies).
Single SNP Analyses
No SNP reached the a priori significance threshold after Bonferroni correction (Table). Four SNPs (rs7909791[SH3PXD2A], OR [95% CI]=1.14 [1.03–1.27]; P=0.01; rs72934505[NBEAL1], OR [95% CI]=1.24 [1.07–1.45]; P=0.004; rs941898[EVL], OR [95% CI]=1.12 [1.01–1.25]; P=0.04; and rs9515201[COL4A2], OR [95% CI]=1.15 [1.03–1.27]; P=0.01) reached a nominal significance threshold in the all lacunar stroke analysis.
Discussion
We used a genetic risk score approach to determine whether genetic variants associated with WMH confer risk of lacunar stroke, and therefore whether WMH and lacunar stroke share pathogenesis. We found strong evidence that genetic variants associated with WMH in community populations also influence risk of lacunar stroke. This provides further evidence to support the long-held view that neuroimaging features of cerebral SVD share pathophysiology. When dividing our lacunar stroke population into those with moderate to severe WMH and those without, we found some evidence for association with both groups, although the association was marginally (and not significantly) stronger in the group with WMH and the association in the group without WMH did not reach Bonferroni-corrected significance. This suggests that variants influencing WMH confer risk of lacunar stroke even for lacunar strokes without substantial WMH. In addition, 2 of the SNPs, rs9515201[COL4A2] and rs2984613[PMF1-BGLAP], are also associated with intracerebral hemorrhage.10,22 This serves to emphasize that shared pathophysiological processes seem to underlie many of the clinical manifestations of cerebral SVD and suggests that a coordinated attempt to identify cerebral SVD associations will likely be fruitful. Four SNPs reached nominal significance for association with lacunar stroke (rs7909791[SH3PXD2A], rs72934505[NBEAL1], rs941898[EVL], and rs9515201[COL4A2]). With the exception of COL4A2, which has been linked to SVD, none of these loci have formerly been linked to ischemic stroke. As discussed above, similar arterial changes have been described in patients with lacunar stroke or WMH,5 including diffuse arteriosclerosis and a more focal microatheroma. Other studies have shown that mechanisms including blood–brain barrier dysfunction,22–24 and endothelial dysfunction,25 are important in both.23 As our results show a shared molecular basis to the 2 traits, they might suggest that these findings are because of the fact that WMH and lacunar stroke are outward manifestations of a shared underlying pathological process, namely, cerebral SVD.
In contrast, a genetic risk score comprising the same 15 SNPs was not associated with large vessel or cardioembolic stroke. Some studies have shown a relationship between subclinical atherosclerosis and WMH,23,24 whereas others have found an increased risk of all stroke in individuals with WMH.25 Our results, in a well-characterized population, suggest that the relationship between WMH and ischemic stroke is limited to lacunar stroke. This finding might suggest that previously reported associations between nonlacunar strokes and WMH may be because of shared risk factors such as hypertension rather than shared pathogenesis.
This study has several strengths. The sample size was large and all lacunar strokes were confirmed by MRI, reducing the possibility of misclassification which might occur when using CT. In addition, the design of the study, which made use of genetic data, means that the results are less susceptible to the residual confounding and reverse causation that observational studies can suffer from, although other sources of confounding, such as technical artifacts, may arise. Similarly, this study has weaknesses. We were unable to evaluate 3 rare SNPs which were associated with WMH in the previous publication,9 which may have affected our results. Some lacunar infarcts were diagnosed as acute lesions on DWI, but others were diagnosed from MRI scans performed after the acute stroke phase as cavities on T1 or fluid-attenuated inversion recovery images. The inclusion of patients defined using these different radiological criteria may introduce a subtle bias, and it is possible that some of these cavities could have resulted from hemorrhage rather than ischemia. Although MRI was performed for all lacunar stroke subjects, it was not performed in all nonlacunar subtypes, which could lead to some degree of misclassification. In addition, controls were historical and MRI was not performed to rule out cerebrovascular disease.
Conclusions
Genetic factors that affect WMH are also associated with risk of lacunar stroke, but not other stroke subtypes. This sheds new light on processes that are implicated in lacunar stroke and provides further evidence that shared pathophysiological processes underlie different manifestations of SVD.
Sources of Funding
H. Markus was supported by an
Disclosures
None.
Footnotes
References
- 1.
Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, ; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.Lancet Neurol. 2013; 12:822–838. doi: 10.1016/S1474-4422(13)70124-8.CrossrefMedlineGoogle Scholar - 2.
Lammie GA . Pathology of small vessel stroke.Br Med Bull. 2000; 56:296–306.CrossrefMedlineGoogle Scholar - 3.
Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, . Heterogeneity in age-related white matter changes.Acta Neuropathol. 2011; 122:171–185. doi: 10.1007/s00401-011-0851-x.CrossrefMedlineGoogle Scholar - 4.
O’Sullivan M . Leukoaraiosis.Pract Neurol. 2008; 8:26–38. doi: 10.1136/jnnp.2007.139428.CrossrefMedlineGoogle Scholar - 5.
Bailey EL, Smith C, Sudlow CL, Wardlaw JM . Pathology of lacunar ischemic stroke in humans–a systematic review.Brain Pathol. 2012; 22:583–591. doi: 10.1111/j.1750-3639.2012.00575.x.CrossrefMedlineGoogle Scholar - 6.
Wen W, Sachdev PS . Extent and distribution of white matter hyperintensities in stroke patients: the Sydney Stroke Study.Stroke. 2004; 35:2813–2819. doi: 10.1161/01.STR.0000147034.25760.3d.LinkGoogle Scholar - 7.
Rost NS, Rahman RM, Biffi A, Smith EE, Kanakis A, Fitzpatrick K, . White matter hyperintensity volume is increased in small vessel stroke subtypes.Neurology. 2010; 75:1670–1677. doi: 10.1212/WNL.0b013e3181fc279a.CrossrefMedlineGoogle Scholar - 8.
Tan RY, Markus HS . Monogenic causes of stroke: now and the future.J Neurol. 2015; 262:2601–2616. doi: 10.1007/s00415-015-7794-4.CrossrefMedlineGoogle Scholar - 9.
Verhaaren BF, Debette S, Bis JC, Smith JA, Ikram MK, Adams HH, . Multiethnic genome-wide association study of cerebral white matter hyperintensities on MRI.Circ Cardiovasc Genet. 2015; 8:398–409. doi: 10.1161/CIRCGENETICS.114.000858.LinkGoogle Scholar - 10.
Rannikmäe K, Davies G, Thomson PA, Bevan S, Devan WJ, Falcone GJ, ; METASTROKE Consortium; CHARGE WMH Group; ISGC ICH GWAS Study Collaboration; WMH in Ischemic Stroke GWAS Study Collaboration; International Stroke Genetics Consortium. Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease.Neurology. 2015; 84:918–926. doi: 10.1212/WNL.0000000000001309.CrossrefMedlineGoogle Scholar - 11.
Ibrahim-Verbaas CA, Fornage M, Bis JC, Choi SH, Psaty BM, Meigs JB, . Predicting stroke through genetic risk functions: the CHARGE Risk Score Project.Stroke. 2014; 45:403–412. doi: 10.1161/STROKEAHA.113.003044.LinkGoogle Scholar - 12.
Malik R, Bevan S, Nalls MA, Holliday EG, Devan WJ, Cheng YC, ; Wellcome Trust Case Control Consortium 2. Multilocus genetic risk score associates with ischemic stroke in case-control and prospective cohort studies.Stroke. 2014; 45:394–402. doi: 10.1161/STROKEAHA.113.002938.LinkGoogle Scholar - 13.
Malik R, Freilinger T, Winsvold BS, Anttila V, Vander Heiden J, Traylor M, ; International Headache Genetics Consortium; METASTROKE Collaboration of the International Stroke Genetics Consortium. Shared genetic basis for migraine and ischemic stroke: A genome-wide analysis of common variants.Neurology. 2015; 84:2132–2145. doi: 10.1212/WNL.0000000000001606.CrossrefMedlineGoogle Scholar - 14.
Fisher CM . Lacunar strokes and infarcts: a review.Neurology. 1982; 32:871–876.CrossrefMedlineGoogle Scholar - 15.
Bellenguez C, Bevan S, Gschwendtner A, Spencer CC, Burgess AI, Pirinen M, . Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke.Nat Genet. 2012; 44:328–333.CrossrefMedlineGoogle Scholar - 16.
Holliday EG, Maguire JM, Evans TJ, Koblar SA, Jannes J, Sturm JW, ; Australian Stroke Genetics Collaborative; International Stroke Genetics Consortium; Wellcome Trust Case Control Consortium 2. Common variants at 6p21.1 are associated with large artery atherosclerotic stroke.Nat Genet. 2012; 44:1147–1151. doi: 10.1038/ng.2397.CrossrefMedlineGoogle Scholar - 17.
Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC, ; Australian Stroke Genetics Collaborative, Wellcome Trust Case Control Consortium 2 (WTCCC2); International Stroke Genetics Consortium. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies.Lancet Neurol. 2012; 11:951–962. doi: 10.1016/S1474-4422(12)70234-X.CrossrefMedlineGoogle Scholar - 18.
Rutten-Jacobs LC, Traylor M, Adib-Samii P, Thijs V, Sudlow C, Rothwell PM, . Common NOTCH3 variants and cerebral small-vessel disease.Stroke. 2015; 46:1482–1487. doi: 10.1161/STROKEAHA.114.008540.LinkGoogle Scholar - 19.
Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke. 1993; 24:35–41.LinkGoogle Scholar - 20.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C . Classification and natural history of clinically identifiable subtypes of cerebral infarction.Lancet. 1991; 337:1521–1526.CrossrefMedlineGoogle Scholar - 21.
Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, . Pathologic correlates of incidental MRI white matter signal hyperintensities.Neurology. 1993; 43:1683–1689.CrossrefMedlineGoogle Scholar - 22.
Wardlaw JM, Doubal F, Armitage P, Chappell F, Carpenter T, Muñoz Maniega S, . Lacunar stroke is associated with diffuse blood-brain barrier dysfunction.Ann Neurol. 2009; 65:194–202. doi: 10.1002/ana.21549.CrossrefMedlineGoogle Scholar - 23.
Farrall AJ, Wardlaw JM . Blood-brain barrier: ageing and microvascular disease–systematic review and meta-analysis.Neurobiol Aging. 2009; 30:337–352. doi: 10.1016/j.neurobiolaging.2007.07.015.CrossrefMedlineGoogle Scholar - 24.
Yang Y, Rosenberg GA . Blood-brain barrier breakdown in acute and chronic cerebrovascular disease.Stroke. 2011; 42:3323–3328. doi: 10.1161/STROKEAHA.110.608257.LinkGoogle Scholar - 25.
Knottnerus IL, Ten Cate H, Lodder J, Kessels F, van Oostenbrugge RJ . Endothelial dysfunction in lacunar stroke: a systematic review.Cerebrovasc Dis. 2009; 27:519–526. doi: 10.1159/000212672.CrossrefMedlineGoogle Scholar
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.